目的 观察环磷腺苷联合阿魏酸钠治疗慢性肾衰竭周围神经病变的临床疗效.方法 收集2012年1月—2014年12月在日照市人民医院住院的84例慢性肾衰竭患者,随机分为对照组和治疗组,每组42例.对照组静脉滴注注射用阿魏酸钠,300 mg加入5%葡萄糖注射液200 mL,1次/d.治疗组静脉滴注注射用环磷腺苷,40 mg加入5%葡萄糖注射液200 mL,1次/d,同时使用注射用阿魏酸钠,其用法用量同对照组.两组均连续治疗4周.观察两组的临床疗效,同时比较两组治疗前后正中神经、腓神经运动神经传导速度(MNCV)和感觉神经传导速度(SNCV)的变化.结果 治疗后,对照组和治疗组的总有效率分别为71.42%、88.10%,两组总有效率比较差异有统计学意义(P< 0.05).两组患者正中神经、腓神经的运动神经传导速度和感觉神经传导速度均较治疗前显著增加,同组治疗前后差异有统计学意义(P< 0.05);且治疗组的改善程度优于对照组,两组比较差异有统计学意义(P< 0.05).结论 环磷腺苷联合阿魏酸钠治疗慢性肾衰竭周围神经病变具有较好的临床疗效,可提高正中神经、腓神经的感觉神经、运动神经的传导速度,值得临床推广应用.

Objective To observe the clinical effect of adenosine cyclphosphate combined with sodium ferulate in treatment of chronic renal failure with peripheral neuropathy. Methods Patients (84 cases) with chronic renal failure in the People's Hospital of Rizhao City from January 2012 to December 2014 were randomly divided into control and treatment groups, and each group had 42 cases. The patients in the control group were iv administered with Adenosine Cyclphosphate for Injection, 300 mg adding 200 mL 5% glucose injection, once daily. The patients in the treatment group were iv administered with Sodium Ferulate for injection, 40 mg adding 200 mL 5% glucose injection, once daily, and the usage and dosage of Adenosine Cyclphosphate for Injection were the same as the control group. Two groups were treated for four weeks. After treatment, the efficacy was evaluated, and the changes of MNCV and SNCV of median nerve and peroneal nerve in two groups were compared. Results The efficacies in the control and treatment groups were 71.42% and 88.10%, respectively, and there were differences between two groups (P <0.05). After treatment, MNCV and SNCV of median nerve and peroneal nerve in two groups were significantly increased, and the difference was statistically significant in the same group (P <0.05). And these indicators in treatment group improved better than those in the control group, with significant difference between two groups (P <0.05). Conclusion Adenosine cyclphosphate combined with sodium ferulate has the good clinical effect in treatment of chronic renal failure with peripheral neuropathy, and can improve MNCV and SNCV of median nerve and peroneal nerve, which is worth clinical promotion.